The French registry of Acute ST elevation or non-ST-elevation Myocardial Infarction (FAST-MI): Study design and baseline characteristics

Archives des Maladies du Coeur et des Vaisseaux

Volumn 100, Issue 6-7, 2007, Pages 524-534

  Cambou, Jean Pierre ^a   Simon, T ^b   Mulak, G ^a   Bataille, V ^a   Danchin, N ^c  

^a Societe Francaise de Cardiologie   (France)

^b HÔPITAL SAINT ANTOINE   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Myocardial infarction (MI); Outcome; Registry; Study design

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; FAMILY HISTORY; FEMALE; FRANCE; HEART INFARCTION; HEART MUSCLE REPERFUSION; HIGH RISK POPULATION; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; MORTALITY; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; REGISTER; SMOKING; ST SEGMENT ELEVATION;

ADRENERGIC BETA-ANTAGONISTS; AGE FACTORS; AGED; AGED, 80 AND OVER; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; DIABETES COMPLICATIONS; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; FRANCE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTENSIVE CARE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; PATIENT ADMISSION; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; REGISTRIES; SEX FACTORS; SMOKING; THROMBOLYTIC THERAPY; TIME FACTORS; TREATMENT OUTCOME;

EID: 34547765997     PISSN: 00039683     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Hasdai D, Behar S, Wallentin L, Danchin N, Gilt AK, Boersma E, Fioretti PM, Simoons ML, Battler A. A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin; the Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS). Eur Heart J. 2002; 23: 1190-201.
2. American Heart Association. Heart and Stroke Statistics-2005 update. Dallas, Tex.: American Heart Association. 2005.
3. Scandinavian Simvastatin Survival Study. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344: 1383-9.
4. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996; 335: 1001-9.
5. HPS. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002; 360: 7-22.
6. Investigators TG. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. N Engl J Med. 1993; 329: 673-82.
7. Andersen HR, Nielsen TT, Rasmussen K, Thuesen L, Kelbaek H, Thayssen P, Abildgaard U, Pedersen F, Madsen JK, Grande P, Villadsen AB, Krusell LR, Haghfelt T, Lomholt P, Husted SE, Vigholt E, Kjaergard HK. Mortensen LS. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med. 2003; 349: 733-42.
8. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003; 361: 13-20.
9. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. Jama. 2001; 285: 1711-8.
10. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004; 350: 1495-504.
11. Gustafsson I, Torp-Pedersen C, Kober L, Gustafsson F, Hildebrandt P. Effect of the angiotensin-converting enzyme inhibitor trandolapril on mortality and morbidity in diabetic patients with left ventricular dysfunction after acute myocardial infarction. Trace Study Group. J Am Coll Cardiol. 1999; 34: 83-9.
12. Torp-Pedersen C, Kober L. Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation. Lancet. 1999; 354: 9-12.
13. Pedersen OD, Bagger H, Kober L, Torp-Pedersen C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation. 1999; 100: 376-80.
14. Hall AS, Murray GD, Ball SG. Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Acute Infarction Ramipril Efficacy. Lancet. 1997; 349: 1493-7.
15. Koren MJ, Hunninghake DB. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study. J Am Coll Cardiol. 2004; 44: 1772-9.
16. LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. N Engl J Med. 1998; 339: 1349-57.
17. Investigators TG. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. N Engl J Med. 1993; 329: 673-82.
18. Investigators TG. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators. N Engl J Med. 1997; 336: 1621-8.
19. Danchin N, Vaur L, Genes N, Etienne S, Angioi M, Ferrieres J, Cambou JP. Treatment of acute myocardial infarction by primary coronary angioplasty or intravenous thrombolysis in the 'real world': one-year results from a nationwide French survey. Circulation. 1999; 99: 2639-44.
20. Danchin N, Vaur L, Genes N, Renault M, Ferrieres J, Etienne S, Cambou JP. Management of acute myocardial infarction in intensive care units in 1995: a nationwide French survey of practice and early hospital results. J Am Coll Cardiol. 1997; 30: 1598-605.
21. Vaur L, Danchin N, Genes N, Dubroca I, Etienne S, Ferrieres J, Cambou JP. Epidemiology of myocardial infarction in France: therapeutic and prognostic implications of heart failure during the acute phase. Am Heart J. 1999; 137: 49-58.
22. Hanania G, Cambou JP, Gueret P, Vaur L, Blanchard D, Lablanche JM, Boutalbi Y, Humbert R, Clerson P, Genes N, Danchin N. Management and in-hospital outcome of patients with acute myocardial infarction admitted to intensive care units at the turn of the century: results from the French nationwide USIC 2000 registry. Heart. 2004; 90: 1404-10.
23. Danchin N, Blanchard D, Steg PG, Sauval P, Hanania G, Goldstein P, Cambou JP, Gueret P, Vaur L, Boutalbi Y, Genes N, Lablanche JM. Impact of prehospital thrombolysis for acute myocardial infarction on 1-year outcome: results from the French Nationwide USIC 2000 Registry. Circulation. 2004; 110: 1909-15.
24. Ferrieres J, Cambou JP, Gueret P, Boutalbi Y, Lablanche JM, Hanania G, Genes N, Cantet C, Danchin N. Effect of early initiation of statins on survival in patients with acute myocardial infarction (the USIC 2000 Registry). Am J Cardiol. 2005; 95: 486-9.
25. Heidenreich PA, Alloggiamento T, Melsop K, McDonald KM, Go AS, Hlatky MA. The prognostic value of troponin in patients with non-ST elevation acute coronary syndromes: a meta-analysis. J Am Coll Cardiol. 2001; 38: 478-85.
26. Franklin K, Goldberg RJ, Spencer F, Klein W, Budaj A, Brieger D, Marre M, Steg PG, Gowda N, Gore JM. Implications of diabetes in patients with acute coronary syndromes. The Global Registry of Acute Coronary Events. Arch Intern Med. 2004; 164: 1457-63.
27. Steg PG, Iung B, Feldman LJ, Cokkinos D, Deckers J, Fox KA, Keil U, Maggioni AP. Impact of availability and use of coronary interventions on the prescription of aspirin and lipid lowering treatment after acute coronary syndromes. Heart. 2002; 88: 20-4.
28. Amar J, Chamontin B, Ferrieres J, Danchin N, Grenier O, Cantet C, Cambou JP. Hypertension control at hospital discharge after acute coronary event: influence on cardiovascular prognosis - the PREVENIR study. Heart. 2002; 88: 587-91.
29. Danchin N, Grenier O, Ferrieres J, Cantet C, Cambou JP. Use of secondary preventive drugs in patients with acute coronary syndromes treated medically or with coronary angioplasty: results from the nationwide French PREVENIR survey. Heart. 2002; 88: 159-62.
30. Zeller M, Cottin Y, Brindisi MC, Dentan G, Laurent Y, Janin-Manificat L, L' Huillier I, Beer JC, Touzery C, Makki H, Verges B, Wolf JE. Impaired fasting glucose and cardiogenic shock in patients with acute myocardial infarction. Eur Heart J. 2004; 25: 308-12.
31. Chambless L, Keil U, Dobson A, Mahonen M, Kuulasmaa K, Rajakangas AM, Lowel H, Tunstall-Pedoe H. Population versus clinical view of case fatality from acute coronary heart disease: results from the WHO MONICA Project 1985-1990. Multinational MONItoring of Trends and Determinants in CArdiovascular Disease. Circulation. 1997; 96: 3849-59.
32. Marques-Vidal P, Ferrieres J, Metzger MH, Cambou JP, Filipiak B, Lowel H, Keil U. Trends in coronary heart disease morbidity and mortality and acute coronary care and case fatality from 1985-1989 in southern Germany and south-western France. Eur Heart J. 1997; 18: 816-21.
33. Hasdaï D, Behar S, Valentin L, Danchin N, Gitt AK. A prospective survey of the characteristics treatment and outcomes of patients with acute coronary syndromes in Europe and Mediterranean bassin: The Euro Heart Survey ACS Eur Heart J 2002; 23: 1190-1201.
34. Fox KAA, Cokkinos DV, Deckers J, Keil U, Maggioni A. The ENACT study: a pan European survey of acute coronary syndromes Eur Heart J 2000; 21: 1440-49.